In practical terms, this means they can help lower blood sugar, reduce hunger, and support weight loss in the right patient
[3] [5] If you are participating in a clinical trial involving a GLP-1 patch, you must follow the specific instructions provided by the research team
Now, two new late-phase clinical trials, sponsored by Eli Lilly and Company, suggest that transitioning from high dose injectable weight loss medications to either a daily pill or a lower maintenance dose can help people living with obesity to keep off most of the weight they have already lost The results of the ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN trials were presented at the European Congress on Obesity and published in Previous research suggests that 1 year after stopping weight loss medication, people may regain, on average, 60% of their lost weight
12/19/2025 M Early Honestly, this duo has been a game changer for me
Shows less excitement or emotional attachment to food during social gatherings
Every GLP-1 receptor agonist causes delayed gastric emptying
